Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | USP19 | O94966 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25701896 | 0.96 | MGLL (0.38) | MGLLALDH1A1TSHRLMNAUSP2 | |
| SCHEMBL23806935 | 0.95 | MGLL (0.40) | MGLLALDH1A1TSHRLMNAUSP2 | |
| SCHEMBL25923532 | 0.91 | MGLL (0.38) | MGLLALDH1A1TSHRLMNAUSP2 | |
| SCHEMBL25707225 | 0.88 | MGLL (0.43) | MGLLALDH1A1TSHRL3MBTL1 | |
| SCHEMBL23696847 | 0.87 | MGLL (0.41) | MGLLALDH1A1TSHRCYP2C19L3MBTL1 | |
| SCHEMBL25479488 | 0.87 | MGLL (0.43) | MGLLALDH1A1TSHRLMNAUSP2 | |
| SCHEMBL23806773 | 0.87 | MGLL (0.42) | MGLLALDH1A1TSHRCYP2C19L3MBTL1 | |
| SCHEMBL23696482 | 0.85 | MGLL (0.39) | MGLLALDH1A1TSHRLMNAUSP2 | |
| SCHEMBL23945287 | 0.84 | MGLL (0.40) | MGLLL3MBTL1 | |
| SCHEMBL25730280 | 0.83 | MGLL (0.39) | MGLLALDH1A1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MGLL 1244/4885ALDH1A1 2776/4885TSHR 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.